We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

88 hedge funds and large institutions have $150M invested in Corbus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 7

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

38% more capital invested

Capital invested by funds: $109M → $150M (+$41.1M)

28% more funds holding

Funds holding: 69 → 88 (+19)

0.27% more ownership

Funds ownership: 1.01% → 1.28% (+0.27%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

81% less call options, than puts

Call options by funds: $263K | Put options by funds: $1.4M

Holders
88
Holders Change
+19
Holders Change %
+27.54%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
33
Reduced
16
Closed
7
Calls
$263K
Puts
$1.4M
Net Calls
-$1.13M
Net Calls Change
-$339K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.63M
2
BlackRock
BlackRock
New York
+$7.11M
3
BBA
Baker Bros. Advisors
New York
+$4.71M
4
GPP
Great Point Partners
Connecticut
+$4.28M
5
Morgan Stanley
Morgan Stanley
New York
+$3.31M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.11M
2
PA
Perceptive Advisors
New York
-$1.53M
3
AA
ALPS Advisors
Colorado
-$354K
4
GCP
GSA Capital Partners
United Kingdom
-$245K
5
NFA
Nationwide Fund Advisors
Ohio
-$179K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Knoll Capital Management
Florida
$27.4M +$842K +3,935 +3%
BlackRock
2
BlackRock
New York
$25.5M +$7.11M +33,226 +38%
Vanguard Group
3
Vanguard Group
Pennsylvania
$15.2M +$2.99M +13,958 +24%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$14.9M +$9.63M +44,997 +181%
IA
5
IFP Advisors
Florida
$7.11M -$1.71K -8 -0%
State Street
6
State Street
Massachusetts
$4.99M +$264K +1,235 +6%
BBA
7
Baker Bros. Advisors
New York
$4.69M +$4.71M +22,024 New
GPP
8
Great Point Partners
Connecticut
$4.26M +$4.28M +20,000 New
Millennium Management
9
Millennium Management
New York
$4M -$2.11M -9,843 -34%
Morgan Stanley
10
Morgan Stanley
New York
$3.98M +$3.31M +15,445 +480%
Northern Trust
11
Northern Trust
Illinois
$3.72M +$160K +746 +4%
RJFSA
12
Raymond James Financial Services Advisors
Florida
$3.09M -$67.6K -316 -2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$2.9M +$271K +1,267 +10%
AG
14
Artal Group
Luxembourg
$2.84M +$1.78M +8,333 +167%
SFM
15
Sphera Funds Management
Israel
$2.66M +$2.68M +12,500 New
EMG
16
ETF Managers Group
New Jersey
$1.81M +$1.62M +7,589 New
Jennison Associates
17
Jennison Associates
New York
$1.6M +$1.61M +7,500 New
PA
18
Perceptive Advisors
New York
$1.42M -$1.53M -7,156 -52%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.35M +$281K +1,314 +26%
Creative Planning
20
Creative Planning
Kansas
$1.27M +$34.7K +162 +3%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$1.14M +$1.15M +5,369 New
CIBC Private Wealth Group
22
CIBC Private Wealth Group
Georgia
$1.03M +$14.8K +69 +1%
Allianz Asset Management
23
Allianz Asset Management
Germany
$844K -$11.3K -53 -1%
TCIM
24
TIAA CREF Investment Management
New York
$821K +$1.93K +9 +0.2%
Deutsche Bank
25
Deutsche Bank
Germany
$814K +$284K +1,326 +53%
1
2 3 4

CRBP Hedge Fund Activity: Q4 2017 in Review

88 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2017, worth a combined $150M — up 38% from $109M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRBP positions and 7 closed out — a net gain of 20 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.63M. The largest seller was Millennium Management, cutting an estimated $2.11M.

  • 88 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2017, up from 69 in Q3 2017.
  • Funds reported $150M of Corbus Pharmaceuticals stock for Q4 2017, up 38% quarter-over-quarter.
  • 27 funds opened new Corbus Pharmaceuticals positions in Q4 2017 and 7 closed out, a net change of +20 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2017 was Fidelity Investments, an estimated $9.63M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $2.11M sold.

Based on aggregated 13F filings for Q4 2017.